Abstract
Purpose
To determine whether TRT in men with hypogonadism is associated with an increased risk of urolithiasis.
Methods
We conducted a population-based matched cohort study utilizing data sourced from the Military Health System Data Repository (a large military-based database that includes beneficiaries of the TRICARE program). This included men aged 40–64 years with no prior history of urolithiasis who received continuous TRT for a diagnosis of hypogonadism between 2006 and 2014. Eligible individuals were matched using both demographics and comorbidities to TRICARE enrollees who did not receive TRT. The primary outcome was 2-year absolute risk of a stone-related event, comparing men on TRT to non-TRT controls.
Results
There were 26,586 pairs in our cohort. Four hundred and eighty-two stone-related events were observed at 2 years in the non-TRT group versus 659 in the TRT group. Log-rank comparisons showed this to be a statistically significant difference in events between the two groups (p < 0.0001). This difference was observed for topical (p < 0.0001) and injection (p = 0.004) therapy-type subgroups, though not for pellet (p = 0.27). There was no significant difference in stone episodes based on secondary polycythemia diagnosis, which was used as an indirect indicator of higher on-treatment testosterone levels (p = 0.14).
Conclusion
We observed an increase in 2-year absolute risk of stone events among those on TRT compared to those who did not undergo this hormonal therapy. These findings merit further investigation into the pathophysiologic basis of our observation and consideration by clinicians when determining the risks and benefits of placing patients on TRT.
Similar content being viewed by others
References
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715–1744. https://doi.org/10.1210/jc.2018-00229
Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363(2):123–135. https://doi.org/10.1056/NEJMoa0911101
Handelsman DJ (2015) Irrational exuberance in testosterone prescribing: When will the bubble burst? Med Care 53(9):743–745. https://doi.org/10.1097/MLR.0000000000000416
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Gill TM, Barrett-Connor E, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Farrar JT, Cella D, Rosen RC, Pahor M, Crandall JP, Molitch ME, Cifelli D, Dougar D, Fluharty L, Resnick SM, Storer TW, Anton S, Basaria S, Diem SJ, Hou X, Mohler ER 3rd, Parsons JK, Wenger NK, Zeldow B, Landis JR, Ellenberg SS, Testosterone Trials I (2016) Effects of testosterone treatment in older men. N Engl J Med 374(7):611–624. https://doi.org/10.1056/NEJMoa1506119
Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363(2):109–122. https://doi.org/10.1056/NEJMoa1000485
Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S (2013) Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 9(7):414–424. https://doi.org/10.1038/nrendo.2013.73
Watson JM, Shrewsberry AB, Taghechian S, Goodman M, Pattaras JG, Ritenour CW, Ogan K (2010) Serum testosterone may be associated with calcium oxalate urolithogenesis. J Endourol 24(7):1183–1187. https://doi.org/10.1089/end.2010.0113
Scales CD Jr, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project (2012) Prevalence of kidney stones in the United States. Eur Urol 62(1):160–165
Lee YH, Huang WC, Huang JK, Chang LS (1996) Testosterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats. J Urol 156(2 Pt 1):502–505
Hsu YJ, Dimke H, Schoeber JP, Hsu SC, Lin SH, Chu P, Hoenderop JG, Bindels RJ (2010) Testosterone increases urinary calcium excretion and inhibits expression of renal calcium transport proteins. Kidney Int 77(7):601–608. https://doi.org/10.1038/ki.2009.522
Naghii MR, Babaei M, Hedayati M (2014) Androgens involvement in the pathogenesis of renal stones formation. PLoS ONE 9(4):e93790. https://doi.org/10.1371/journal.pone.0093790
Cole AP, Hanske J, Jiang W, Kwon NK, Lipsitz SR, Kathrins M, Learn PA, Sun M, Haider AH, Basaria S (2018) Impact of testosterone replacement therapy on thromboembolism, heart disease and obstructive sleep apnoea in men. BJU Int 121(5):811–818
Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S (2008) Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 93(3):914–919. https://doi.org/10.1210/jc.2007-1692
Maclean A, Edwards RD (2010) The pervasive role of rank in the health of U.S. Veterans. Armed Forces Soc 36(5):765–785. https://doi.org/10.1177/0095327x09356166
Matlaga BR, Shore AD, Magnuson T, Clark JM, Johns R, Makary MA (2009) Effect of gastric bypass surgery on kidney stone disease. J Urol 181(6):2573–2577. https://doi.org/10.1016/j.juro.2009.02.029
Semins MJ, Shore AD, Makary MA, Magnuson T, Johns R, Matlaga BR (2010) The association of increasing body mass index and kidney stone disease. J Urol 183(2):571–575. https://doi.org/10.1016/j.juro.2009.09.085
Rosen RC, Wu F, Behre HM, Porst H, Meuleman EJH, Maggi M, Romero-Otero J, Martinez-Salamanca JI, Jones TH, Debruyne FMJ, Kurth KH, Hackett GI, Quinton R, Stroberg P, Reisman Y, Pescatori ES, Morales A, Bassas L, Cruz N, Cunningham GR, Wheaton OA, Investigators R (2017) Quality of life and sexual function benefits of long-term testosterone treatment: longitudinal results from the registry of hypogonadism in men (RHYME). J Sex Med 14(9):1104–1115. https://doi.org/10.1016/j.jsxm.2017.07.004
Ohlander SJ, Varghese B, Pastuszak AW (2018) Erythrocytosis following testosterone therapy. Sex Med Rev 6(1):77–85. https://doi.org/10.1016/j.sxmr.2017.04.001
Rhoden EL, Morgentaler A (2004) Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350(5):482–492. https://doi.org/10.1056/NEJMra022251
Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85(8):2670–2677. https://doi.org/10.1210/jcem.85.8.6731
Naghii MR, Hedayati M (2010) Determinant role of gonadal sex hormones in the pathogenesis of urolithiasis in a male subject—a document for male predominancy (case study). Endocr Regul 44(4):143–146
Gupta K, Gill GS, Mahajan R (2016) Possible role of elevated serum testosterone in pathogenesis of renal stone formation. Int J Appl Basic Med Res 6(4):241
Yoshihara H, Yamaguchi S, Yachiku S (1999) Effect of sex hormones on oxalate-synthesizing enzymes in male and female rat livers. J Urol 161(2):668–673
Soundararajan P, Mahesh R, Ramesh T, Begum VH (2006) Effect of Aerva lanata on calcium oxalate urolithiasis in rats. Indian J Exp Biol 44(12):981–986
Lee YH, Huang WC, Chiang H, Chen MT, Huang JK, Chang LS (1992) Determinant role of testosterone in the pathogenesis of urolithiasis in rats. J Urol 147(4):1134–1138
Fan J, Glass MA, Chandhoke PS (1998) Effect of castration and finasteride on urinary oxalate excretion in male rats. Urol Res 26(1):71–75
Yagisawa T, Ito F, Osaka Y, Amano H, Kobayashi C, Toma H (2001) The influence of sex hormones on renal osteopontin expression and urinary constituents in experimental urolithiasis. J Urol 166(3):1078–1082
Worcester EM, Nakagawa Y, Coe FL (1987) Glycoprotein calcium oxalate crystal growth inhibitor in urine. Miner Electrolyte Metab 13(4):267–272
Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL (1992) The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7(9):1029–1036. https://doi.org/10.1002/jbmr.5650070905
Changtong C, Peerapen P, Khamchun S, Fong-Ngern K, Chutipongtanate S, Thongboonkerd V (2016) In vitro evidence of the promoting effect of testosterone in kidney stone disease: a proteomics approach and functional validation. J Proteom 144:11–22. https://doi.org/10.1016/j.jprot.2016.05.028
Acknowledgements
The Center for Surgery and Public Health and the Uniformed Services University of Health Sciences are jointly supported by the Henry M. Jackson Foundation for the Advancement of Military Medicine to provide protected research efforts involving the analysis and study of military TRICARE data (Grant # HU0001-11-1- 0023). The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views, assertions, opinions, or policies of the Uniformed Services University of the Health Sciences (USUHS), the United States Department of Defense (DoD), or any other agency.
Funding
Dr. Haider reports receiving grants from the Henry M. Jackson Foundation of the Department of Defense, the Orthopaedic Research and Education Foundation, and the National Institutes of Health, and non-financial research supports from the Centers for Medicare and Medicaid Services Office of Minority Health. Dr. Trinh reports receiving research support from the Brigham Research Institute Fund to Sustain Research Excellence, the Bruce A. Beal and Robert L. Beal Surgical Fellowship, the Genentech Bio-Oncology Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (Grant # 10202), a Health Services Research pilot test grant from the Defense Health Agency, the Clay Hamlin Young Investigator Award from the Prostate Cancer Foundation (Grant # 16YOUN20), and an unrestricted educational grant from the Vattikuti Urology Institute.
Author information
Authors and Affiliations
Contributions
TRM, M-TI, TK, SB, and Q-DT developed the protocol/project, were involved in data collection or management, analyzed and interpreted the data, and wrote/edited the manuscript. NKK developed the protocol/project, was involved in data collection or management, analyzed the data, and wrote/edited the manuscript. APC, MNK, NB, GEH, and AHH analyzed and interpreted the data and wrote/edited the manuscript. WJ analyzed the data and wrote/edited the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Dr. Basaria reports receiving consulting fees from Eli Lilly and Takeda Pharmaceuticals. Dr. Trinh reports receiving consulting fees from Bayer, Astellas, and Janssen. All other authors have nothing to disclose.
Human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
For this type of study, formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendices
Appendix 1: Study cohort selection and matching
Appendix 2: Codes for diagnoses and procedures
Diagnosis | ICD-9 diagnosis | |
---|---|---|
Testicular dysfunction | 257.1–257.9 | |
Procedure | ICD-9 procedure | HCPCS/CPT |
Testosterone pellet; 75 mg | S0189/11980 | |
Injection, testosterone enanthate and estradiol valerate, up to 1 cc | J0900 | |
Injection, testosterone cypionate and estradiol cypionate, up to 1 ml | J1060 | |
Injection, testosterone cypionate, up to 100 mg | J1070 | |
Injection, testosterone cypionate, 1 cc, 200 mg | J1080 | |
Injection, nandrolone decanoate, up to 50 mg | J2320 | |
Injection, testosterone enanthate, up to 100 mg | J3120 | |
Injection, testosterone enanthate, up to 200 mg | J3130 | |
Injection, testosterone suspension, up to 50 mg | J3140 | |
Injection, testosterone propionate, up to 100 mg | J3150 | |
Unclassified drug (Testopel) | J3490 | |
Topical formulations (by name) | ||
AndroGel | ||
Axiron | ||
Fortesta | ||
Testim | ||
Vogelxo | ||
Oral formulations (by name) | ||
Android | ||
Methitest | ||
Oxandrin | ||
Oxandrolone | ||
Testred |
Indicators of urolithiasis | ICD-9 | CPT |
---|---|---|
ESWL | 98.5 Extracorporeal shock wave lithotripsy | 50590 Lithotripsy, extracorporeal shock wave |
98.51 Extracorporeal shock wave lithotripsy of the kidney, ureter and/or bladder | S0400 Global fee for extracorporeal shock wave lithotripsy treatment of kidney stone(s) | |
Lithotripsy | 52352 Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with removal or manipulation of calculus | |
52353 Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with lithotripsy | ||
Nephrolithotomy (percutaneous and open) | 55.03 Nephrostomy | 50060 Nephrolithotomy; removal of calculus |
50065 Nephrolithotomy; secondary surgical operation for calculus | ||
50070 Nephrolithotomy; complicated by congenital kidney abnormality | ||
50075 Nephrolithotomy; removal of large staghorn calculus filling renal pelvis and calices | ||
50080 Percutaneous nephrostolithotomy or pyelostolithotomy, up to 2 cm | ||
50081 Percutaneous nephrostolithotomy or pyelostolithotomy, over 2 cm | ||
Urinary calculi | 274.11 Uric acid nephrolithiasis | |
592 Calculus of kidney and ureter | ||
592.1 Calculus of ureter | ||
592.0 Calculus of kidney—nephrolithiasis not otherwise specified | ||
592.9 Urinary calculus, unspecified |
Appendix 3: Occurrence of stone events among those diagnosed with secondary polycythemia within the testosterone replacement therapy cohort of hypogonadal men in TRICARE, 2006–2014
Number of individuals | Individuals with stone event | Percent with stone event | |
---|---|---|---|
No polycythemia diagnosis | 26,093 | 1035 | 3.97 |
Polycythemia diagnosis | 493 | 26 | 5.27 |
Rights and permissions
About this article
Cite this article
McClintock, T.R., Valovska, MT.I., Kwon, N.K. et al. Testosterone replacement therapy is associated with an increased risk of urolithiasis. World J Urol 37, 2737–2746 (2019). https://doi.org/10.1007/s00345-019-02726-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-019-02726-6